Format

Send to

Choose Destination
PLoS One. 2014 Apr 7;9(4):e92548. doi: 10.1371/journal.pone.0092548. eCollection 2014.

Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited.

Author information

1
Université Paris 13, Sorbonne Paris Cité - Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre d'Epidémiologie et Biostatistiques (EPIBIOS), Inserm, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.
2
Département de Biochimie-Pharmacologie-Toxicologie, Centre Hospitalier Universitaire, Grenoble, France.
3
Université Paris 13, Sorbonne Paris Cité - Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre d'Epidémiologie et Biostatistiques (EPIBIOS), Inserm, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France; Université Paris-Descartes, Faculté de Médecine, AP-HP; Hôtel-Dieu, Centre de Diagnostic et Thérapeutique, Paris, France.
4
Université Paris 13, Sorbonne Paris Cité - Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), Centre d'Epidémiologie et Biostatistiques (EPIBIOS), Inserm, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France; Département de Santé publique, Hôpital Avicenne, Bobigny, France.

Abstract

OBJECTIVE:

We aimed to investigate the association between baseline plasma fatty acids profile and the risk of future major cardiovascular events in patients with a history of ischaemic heart disease or ischemic stroke.

METHODS:

Baseline plasma fatty acids as well as established cardiovascular risk factors were measured in 2,263 patients enrolled in the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids randomized controlled trial. Incident major cardiovascular, cardiac and cerebrovascular events were ascertained during the 4.7 years of follow up. Hazard ratios were obtained from Cox proportional hazards models after adjustment for cardiovascular risk factors.

RESULTS:

During the follow-up, 154, 379 and 84 patients had major cardiovascular, cardiac and cerebrovascular events respectively. Upon adjustment for gender, initial event, baseline age and BMI, the risk of developing a major cardiovascular event decreased significantly in successive quartiles of arachidonic acid (P trend<0.002), total omega 3 polyunsaturated fatty acids (P trend<0.03), docosapentaenoic acid (P trend<0.019), docosahexaenoic acid (P trend<0.004), eicosapentaenoic acid + docosahexaenoic acid (P trend<0.03) and eicosapentaenoic acid + docosapentaenoic acid + docosahexaenoic acid (P trend<0.02). This inverse association was borderline significant with increased quartiles of stearidonic acid (P trend<0.06). In the full model, only stearidonic acid remained inversely associated with the risk of developing a major cardiovascular event (P trend<0.035), a cardiac event (P trend<0.016) or a cerebrovascular event (P trend<0.014), while arachidonic acid was inversely associated with the risk a cerebrovascular event (P trend<0.033).

CONCLUSION:

The inverse association of long chain omega 3 polyunsaturated fatty acids with recurrence of Cardiovascular diseases was mainly driven by well-known cardiovascular risk factors.

TRIAL REGISTRATION:

Controlled-Trials.com ISRCTN41926726.

PMID:
24710321
PMCID:
PMC3977829
DOI:
10.1371/journal.pone.0092548
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center